HGEN News and Press, Humanigen Inc. From 09/01/20

80% reduction in relative risk of invasive mechanical ventilation and/or death in patients treated with lenzilumab compared to the control group Median time to resolution of acute respiratory distress syndrome (ARDS) reduced to one day for patients treated with lenzilumab versus ei...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...

Mr. Jordan to build commercial infrastructure in advance of potential Emergency Use Authorization of lenzilumab Humanigen, Inc. , (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called &#...

Seres Therapeutics stock jumps on positive topline data Seres Therapeutics Inc. ( MCRB ) stock recorded swift boost as the company announced positive data from its Phase 3 ECOSPOR III study. The company reported that the drug candidate was able to bring about statistically significant ch...

Relief Therapeutics Holdings AG ( RLFTF ) is a Swiss Company that trades on the U.S. OTC Exchange in addition to its Swiss Stock Exchange Listing (RLF). Only a week ago, Relief Therapeutics was trading under .10 per share. It was the rediscovery of the properties of their drug RLF-100, a propr...

Brazil's Anvisa regulatory agency has signed off on a Phase 3 clinical trial evaluating Humanigen's ( OTCQB:HGEN +2.4% ) lead drug lenzilumab in hospitalized severely ill and critically ill COVID-19 patients at high risk of disease progression. More news on: Humanigen, Inc., Healthcare...

Study approval by Brazil’s ministry of health follows IND approval granted by the FDA in the US Brazil represents an important component of Humanigen’s global development program for lenzilumab Humanigen, Inc. , (HGEN) (“Humanigen”), a clinical ...

Management presentation today, August 10 at 2:00 pm EDT Humanigen, Inc. , (HGEN) (“Humanigen”), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and bu...

Role will build on existing Humanigen Asia-Pacific activities and focus on regional clinical development, commercialization, business and corporate development BURLINGAME, CA / ACCESSWIRE / August 6, 2020 / Humanigen, Inc . (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceu...

Management presentation Monday, August 10 at 2:00 pm EDT Humanigen, Inc. , (HGEN) (“Humanigen”), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer and Dale Chappell, MD, MBA, Chief Scientific Officer of Humanigen will present a company overview and b...